Compare · ELMD vs TMDX
ELMD vs TMDX
Side-by-side comparison of Electromed Inc. (ELMD) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELMD and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.57B, about 7.7x ELMD ($335.5M).
- Over the past year, ELMD is up 115.1% and TMDX is down 29.8% - ELMD leads by 144.9 points.
- TMDX has been more active in the news (5 items in the past 4 weeks vs 1 for ELMD).
- TMDX has more recent analyst coverage (18 ratings vs 3 for ELMD).
- Company
- Electromed Inc.
- TransMedics Group Inc.
- Price
- $40.33-0.35%
- $74.21+1.01%
- Market cap
- $335.5M
- $2.57B
- 1M return
- +6.38%
- -5.83%
- 1Y return
- +115.09%
- -29.82%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2011
- 2019
- News (4w)
- 1
- 5
- Recent ratings
- 3
- 18
Electromed Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest ELMD
- Chief Financial Officer Nagel Bradley M. covered exercise/tax liability with 674 shares, decreasing direct ownership by 3% to 18,964 units (SEC Form 4) (for tax liability)
- CEO and President Cunniff James L. exercised 9,700 shares at a strike of $17.25 and sold $354,095 worth of shares (9,700 units at $36.50) (SEC Form 4)
- Chief Financial Officer Nagel Bradley M. exercised 9,601 shares at a strike of $10.50 and sold $428,936 worth of shares (11,801 units at $36.35), decreasing direct ownership by 10% to 19,638 units (SEC Form 4)
- SEC Form SD filed by Electromed Inc.
- Director Skarvan Kathleen exercised 40,000 shares at a strike of $3.82 and sold $1,419,358 worth of shares (40,000 units at $35.48) (SEC Form 4)
- SEC Form 10-Q filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
- Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Electromed Inc.
Latest TMDX
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)